antifungal agent

(redirected from econazole)
Also found in: Dictionary, Medical, Encyclopedia, Wikipedia.
References in periodicals archive ?
Econazole and miconazole have also been used intravenously, but absorbed levels are usually too low for treatment of systemic mycoses.
EcoNail is the company's patented lacquer which contains the antifungal econazole and MacroChem's enhancer SEPA.
In Switzerland, three triazoles (terconazole, itraconazole, fluconazole) and eight imidazoles (clotrimazole, miconazole, econazole, ketoconazole, tioconazole, isoconazole, oxiconazole, and fenticonazole) are in use (Documed AG 2002).
NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has entered into an agreement to purchase the topical pharmaceutical product Econazole Nitrate Cream 1% from Prasco, LLC.
While there have been some changes in the econazole market earlier this quarter, we have regained market share for that product again over the last two months.
ECOZA(TM) FOAM, a novel alternative for the treatment of interdigital tinea pedis (athletes foot between the toes), combines the proven antifungal efficacy of econazole nitrate with the skin-restoring properties of Proderm Technology.
Approvals were granted for the topical corticosteroid Amcinonide Cream, bioequivalent to Fujisawa's Cyclocort(R) Cream, and the topical antifungals Ketoconazole Cream and Econazole Cream, bioequivalent to Janssen's Nizoral(R) Cream and Ortho's Spectazole(R) Cream, respectively.
Food and Drug Administration (FDA) of its supplemental filing for the site transfer of econazole nitrate cream 1%, to the company's manufacturing facility in Buena, NJ.
These applications include the topical delivery of drugs for the treatment of erectile dysfunction (impotency) which have been proven effective in treating this disorder when injected into the penis, topically applied ibuprofen and ketoprofen for the treatment of muscular and joint pain, econazole for the treatment of fungal infections and acyclovir for the treatment of oral and genital herpes virus infections.
We have solidified our market position in our first three IGI labeled topical pharmaceutical products, and we have successfully launched our fourth product, econazole nitrate cream 1%, which we acquired earlier this year, during the third quarter of 2013.
8 million related to price protection for our customers after our price increase for econazole nitrate cream 1% took effect in September.
Looking forward, as a result of recent changes in our customer mix and market pricing, particularly for econazole nitrate, we anticipate revenue from our econazole nitrate cream products to decline in the second quarter of 2015.